









Markets
/
Stocks
/
nasdaq-annx
/

Annexon Inc

ANNX

2.640USD

+0.120+4.76%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

289.96MMarket Cap

LossP/E TTM



Annexon Inc

2.640

+0.120+4.76%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

193 / 507

Overall Ranking

340 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 8 analysts

Buy

Current Rating

11.600

Target Price

+337.74%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.

Fairly Valued

The company’s latest PE is -1.96, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 116.41M shares, decreasing 14.12% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 5.37M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -1.96, which is -10.61% below the recent high of -1.76 and -60.18% above the recent low of -3.15.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 193/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.50, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Annexon Inc is 11.00, with a high of 14.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.50

Change

Support & Resistance

No Data

Analyst Rating

Based on 8 analysts

Buy

Current Rating

11.600

Target Price

+360.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Annexon Inc

ANNX

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.69, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 2.81 and the support level at 2.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.96

Change

-1.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.121

Buy

RSI(14)

61.070

Neutral

STOCH(KDJ)(9,3,3)

81.328

Neutral

ATR(14)

0.168

High Vlolatility

CCI(14)

105.675

Buy

Williams %R

10.294

Overbought

TRIX(12,20)

0.234

Sell

StochRSI(14)

68.363

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.544

Buy

MA10

2.406

Buy

MA20

2.270

Buy

MA50

2.372

Buy

MA100

2.295

Buy

MA200

2.851

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 106.10%, representing a quarter-over-quarter increase of 4.27%. The largest institutional shareholder is The Vanguard, holding a total of 5.37M shares, representing 4.88% of shares outstanding, with 5.87% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Fidelity Management & Research Company LLC

13.26M

-6.76%

Alerce Investment Management, L.P.

7.41M

BlackRock Institutional Trust Company, N.A.

7.62M

+0.73%

BVF Partners L.P.

7.00M

Redmile Group, LLC

6.30M

The Vanguard Group, Inc.

Star Investors

5.36M

-3.02%

Bain Capital Life Sciences Investors, LLC

5.25M

Bellevue Asset Management AG

5.16M

Sio Capital Management, LLC

3.40M

+43.55%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.01, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.31. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.